Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity

Journal of Medicinal Chemistry

Volumn 41, Issue 10, 1998, Pages 1561-1567

  Njoroge, F George ^a   Vibulbhan, Bancha ^a   Pinto, Patrick ^a   Bishop, W Robert ^a   Bryant, Mathew S ^a   Nomeir, Amin A ^a   Lin, C C ^a   Liu, Ming ^a   Doll, Ronald J ^a   Girijavallabhan, V ^a   Ganguly, Ashit K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN;

ADMINISTRATION, ORAL; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CYCLIC N-OXIDES; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEIN P21(RAS); PYRIDINES; TUMOR CELLS, CULTURED;

EID: 15444345862     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980013b     Document Type: Article

References (21)

1. Barbacid, M. Ras genes Annu. Rev. Biochem. 1987, 56, 779-827.
2. (a) Willumsen, B. M.: Norris, K.; Papageorge, A. G.; Hubbert, N. L.; Lowry, D. R. Harvey murine Sarcoma virus p21 ras protein: Biological and biochemical significance of the cysteine nearest the carboxyl terminus. EMBO J. 1984, 3, 2581-2585
3. (b) Lowry, D. R.; Willumsen, B. M.; New clue to the ras lipid glue Nature (London) 1989, 341, 384-385.
4. (a) Gibbs, J. B.; Oliff, A.; Kohl, N. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutics. Cell 1994, 77, 175-178.
5. (b) Der, C.; Cox, A. D. Isoprenoid modification and plasma membrane association: critical factors for Ras oncogenicity. Cancer Cells 1991, 3, 331-340.
6. Hancock, J. F.; Magee, J. E.; Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57, 1167-1177.
7. Casey, P. J.; Solski, P. A.; Der, C. I.; Buss, J. E. p21 Ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. U.S.A, 1989, 86, 8223-8327.
8. Gibbs, J. B. Ras C-Terminal Processing Enzyme-New Drug Targets. Cell 1991, 65, 1-4.
9. For a recent review, see: Graham, S. L. Inhibitors of protein farnesylation: a new approach to cancer chemotherapy. Exp. Opin. Ther. Pat. 1995, 5, 1269-1285.
10. Leonard, D. M. Ras farnesyltransferase: a new therapeutic target. J. Med. Chem. 1997, 40, 2971-2990.
11. Perrin D.; Halazy, S.; Hill, B. T. Inhibitors of ras signal transduction as a potential antitumour agents. J. Enzyme Inhibn. 1996, 11, 77-95.
12. McNamara D. J.; Dobrusin, E. Leonard, D. M.; Shuler K. R.; Kaltenbronn, J. S.; Quin, J., III; Bur, S.; Thomas, C. E.; Doherty, A. M.; Scholten, J. D.; Zimmerman, K. K.; Gibbs, B. S.; Gowan, R. C.; Latash, M. P.; Leopold, W. R.; Przybranowski, S. A.; Sebolt-Leopold, J. S. C-Terminal modification of histidyl-N-benzylglycinamides to give improved inhibition of ras farnesyltransferase, cellular activity and anti-cancer activity in mice. J. Med. Chem. 1997, 40, 3319-3322.
13. Mallams, A. K.; Njoroge, F. G.; Doll, R. J.; Snow, M. E.; Kaminiski, J. J.; Rossman, R. R.; Vibulbhan, B.; Bishop, W. R.; Kirschmeier, P.; Liu, M.; Bryant, M. S.; Alvarez, C. S.; Carr, D.; James L.; King, I.; Li, Z.; Lin, C.-C.; Petrin, J.; Remiszewski, S. R.; Taveras, A, G.; Wang, S.; Wong, J. K.; Catino, J.; Girijavallabhan, V.; Ganguly, A. K. Antitumor 8-chlorobenzo-cycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of Ras Farnesylation. Bioorg. Med. Chem. 1997, 5, 93-99.
14. Njoroge, F. G.; Doll, R. J.; Vibulbhan, B.; Alvarez, C. S.; Bishop, W. R.; Petrin, J.; Kirschmeier, P.; Carruthers, N. I.; Wong, J. K.; Albanese, M. A.; Piwinski, J. J.; Catino, J.; Girijavailabhan, V.; Ganguly, A. K. Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase. Bioorg. Med. Chem. 1997, 5, 101-113.
15. Njoroge, F. G.; Vibulbhan, B., Dinananth F. Rane, D. F.; Bishop, W. R.; Petrin, J.; Patton, R.; Bryant, M. S.; Chen, K.-J.: Nomeir, A. A.; Lin, C.-C.; Liu, M.; King, I.; Chen, J.; Lee, S.; Yaremko, B.; Dell, J.; Lipari, P.; Malkowski, M.; Li, Z.; Catino, J.; Doll, R. J.; Girijavallabhan, V.; Ganguly, A. K. Structure-activity relationship of 3-substituted N-pyridinylacetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b] pyridinyl-ll-yIidene)piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds. J. Med. Chem. 1997, 40, 4290-4301.
16. Njoroge, F. G.; Vibulbhan, B.; Pinto, P.; Chan, T.-M.; Osterman, R.; Remiszewski, S.; Rosario, J. D.; Doll, R.; Girijavallabhan, V.; Ganguly, A. K. Highly regioselective nitration reactions provide a versatile method of functionalizing benzocycloneptapyridine tricyclic ring systems: Application towards preparation of nanomolar inhibitors of farnesyl protein transferase. J. Org. Chem 1998, 63, 445-451.
17. Wong, J.; Piwinski, J. J.; Green, M. J.; Ganguly, A. K.; Anthes, J. C.; Billah, M. M. Dual antagonists of platelet activating factor and histamine. 2. pyridine ring substitution of N-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta [1,2-blpyridin-11ylidene)piperidine Bioorg. Med. Chem. Lett. 1993, 3, 1073-1078.
18. Schumacher, D. P.; Murphy, B. L.; Clark, J. E.; Tahbaz, P.; Mann, T. A.; Super acid cyclodehydration of ketones in the production of tricyclic antihistamines. J. Org. Chem. 1989, 54, 2242-2244.
19. Bishop, W. R.; Bond, R.; Petrin, J.; Wang, L.; Patton, R.; Doll, R.; Njoroge, G.; Catino, J.; Shwartz, J.; Carr, D.; James, L.; Kirschmeier, P. Novel tricyclic inhibitors of Farnesyl Transferase. J. Biol. Chem. 1995, 270, 30611-30618.
20. Piwinski, J. J.; Wong, J. K.; Chan, T.-M.; Green, M. J.; Ganguly, A. K. Hydroxylated metabolites of Loratadine: An example of conform a tional diastereomers due to atropisomerism. J. Org. Chem. 1990, 55, 3341-3350.
21. Bryant, M. S.; Korfmacher W. A.; Wang, S.; Nardo, C.; Nomeir, A. A.; Lin, C.-C. Pharmacokinetic screening for selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. J. Chromatogr. 1997, 777, 61-66.